On December 16, 2025, Inhibrx Biosciences reported progress on its clinical trials, including 46 of 60 patients recruited for a study on INBRX-106 combined with Keytruda for head and neck cancer, and updates on trials for colorectal cancer and Ewing sarcoma. The results are expected to mature by mid-2026, which could influence future treatment options.